Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4538-23 nivolumab vs chemotherapy in platinum-resistant ovarian cancer
jRCT2080222952Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Ono Pharmaceutical. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2080222952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222952.